Mutation as a Toxicological Endpoint for Regulatory Decision-Making

被引:44
|
作者
Heflich, Robert H. [1 ]
Johnson, George E. [2 ]
Zeller, Andreas [3 ]
Marchetti, Francesco [4 ]
Douglas, George R. [4 ]
Witt, Kristine L. [5 ]
Gollapudi, B. Bhaskar [6 ]
White, Paul A. [4 ]
机构
[1] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA
[2] Swansea Univ, Swansea, W Glam, Wales
[3] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Roche Innovat Ctr Basel, Basel, Switzerland
[4] Hlth Canada, Environm Hlth Sci & Res Bur, Ottawa, ON, Canada
[5] NIEHS, NIH, POB 12233, Res Triangle Pk, NC 27709 USA
[6] Exponent Inc, Alexandria, VA USA
关键词
germ cell mutation; somatic cell mutation; somatic mosaicism; point of departure; error-corrected next-generation sequencing; GENETIC TOXICOLOGY; SOMATIC MOSAICISM; MOUSE; GENOTOXICITY; TOXICITY; EXPOSURE; LOCUS; DNA; CHEMICALS; RADIATION;
D O I
10.1002/em.22338
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Mutations induced in somatic cells and germ cells are responsible for a variety of human diseases, and mutation per se has been considered an adverse health concern since the early part of the 20th Century. Although in vitro and in vivo somatic cell mutation data are most commonly used by regulatory agencies for hazard identification, that is, determining whether or not a substance is a potential mutagen and carcinogen, quantitative mutagenicity dose-response data are being used increasingly for risk assessments. Efforts are currently underway to both improve the measurement of mutations and to refine the computational methods used for evaluating mutation data. We recommend continuing the development of these approaches with the objective of establishing consensus regarding the value of including the quantitative analysis of mutation per se as a required endpoint for comprehensive assessments of toxicological risk. Environ. Mol. Mutagen. 2019. (c) 2019 Wiley Periodicals, Inc.
引用
收藏
页码:34 / 41
页数:8
相关论文
共 50 条
  • [31] THE USE OF TECHNOLOGY IN ADMINISTRATIVE DECISION-MAKING AND IN REGULATORY COMPLIANCE
    ZELANO, AJ
    SHUBIN, HB
    HEANEY, BP
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1992, 204 : 14 - CHAL
  • [32] Risk perception, safety goals and regulatory decision-making
    Hoegberg, L
    RELIABILITY ENGINEERING & SYSTEM SAFETY, 1998, 59 (01) : 135 - 139
  • [33] Interest groups and the government decision-making of regulatory policies
    Wu Qun-Li
    Yao Jin-An
    PROCEEDINGS OF 2007 INTERNATIONAL CONFERENCE ON PUBLIC ADMINISTRATION (3RD), VOL I, 2007, : 830 - 835
  • [34] Documenting Regulatory Requirements Decision-Making as a Compliance Concern
    Kempe, Evelyn
    2022 30TH IEEE INTERNATIONAL REQUIREMENTS ENGINEERING CONFERENCE (RE 2022), 2022, : 213 - 218
  • [35] THE POLITICS OF GOVERNMENT DECISION-MAKING - A THEORY OF REGULATORY CAPTURE
    LAFFONT, JJ
    TIROLE, J
    QUARTERLY JOURNAL OF ECONOMICS, 1991, 106 (04): : 1089 - 1127
  • [36] Political Independence, Accountability, and the Quality of Regulatory Decision-Making
    Koop, Christel
    Hanretty, Chris
    COMPARATIVE POLITICAL STUDIES, 2018, 51 (01) : 38 - 75
  • [37] RISK-BENEFIT ANALYSIS IN REGULATORY DECISION-MAKING
    HIGHLAND, JH
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1979, 329 (OCT) : 263 - 266
  • [38] The Non-Pharmacological Basis of Regulatory Decision-Making
    Ahmad, Syed Rizwanuddin
    Avorn, Jerome
    Raine, June M.
    Leufkens, Hubert
    Park, Byung-Joo
    Aljadhey, Hisham S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 4 - 4
  • [40] Shared Decision-Making Is Not Patient Decision-Making
    Birnbrich, Alysa
    McCulloch, Patrick C.
    Kraeutler, Matthew J.
    SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH, 2023, 15 (04): : 615 - 616